New immune booster aims to stop childhood cancer relapse after transplant
NCT ID NCT07518654
First seen Apr 25, 2026 · Last updated May 18, 2026 · Updated 3 times
Summary
This early-phase trial tests a new therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy uses specially designed immune cells to help the body's natural killer cells better attack any remaining cancer cells. The main goal is to see if the treatment is safe and feasible, with a focus on side effects and dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOETIC STEM CELL TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Sainte-Justine
Montreal, Quebec, H3T1C5, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Hospital for Sick Children
Toronto, Ontario, M5G1E8, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.